RxNews Recap for Monday 01-11-10 Print E-mail
By Mary Davila   
Monday, 11 January 2010 19:06

Below is a list of the companies that made news in the healthcare sector on Monday, January 11, 2010.


Biotech investors interested in seeing more details about these companies and a full list of their related stories can do so by typing the stock ticker symbol into the Stock Quotes box on the right side of the page.

AMAG Pharmaceuticals (NASDAQ:AMAG) expects 13 Million in sales for its drug Feraheme, topping Wall Street forecasts for the 4th quarter by a wide margin. Analyst had expected around $9.3 million for the drug which is intended to treat anemia in patients with chronic kidney disease.

A.P. Pharma, Inc. (Nasdaq:APPA), a specialty pharmaceutical company, today announced that, on January 7, 2010, it received notice from the Nasdaq Stock Market (Nasdaq) confirming that the Company has regained compliance with the $1.00 minimum closing bid price requirement for continued listing on The Nasdaq Capital Market under Listing Rule 5450(a)(1). Pursuant to Nasdaq's rules, the Company was required to achieve a closing bid price of at least $1.00 per share for 10 consecutive trading days which was completed on January 4, 2010.

Cannabis Science Inc. (NASD OTCBB: CBIS), an emerging pharmaceutical cannabis company, is pleased to announce Cannabis Science is in negotiations with several companies in the US and internationally to contract or license its formulations for development, certain rights to manufacturing processes, and the sale in each prospective jurisdiction and or country.

Cel-Sci Corp (AMEX:CVM) completed the validation of its manufacturing facility and can begin manufacturing Multikine for phase 3 clinical trials with head and neck cancer patients. The facility will also be available to other manufacturers on a contract basis.

Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it has decided to suspend operations at its Preclinical Services (PCS) facility in Shrewsbury, Massachusetts, by the middle of 2010, when ongoing in-life studies will have been completed. Charles River intends to resume operations when global preclinical market conditions improve and the Company requires additional capacity.

Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced total revenues for both the fourth quarter and full year ended December 31, 2009.

Cytokinetics, Incorporated (NASDAQ: CYTK) announced positive data from Part B of its Phase I, first-time-in-humans, randomized, double-blind, placebo-controlled, clinical trial of CK-2017357 in healthy volunteers.

A.P. Pharma, Inc. (Nasdaq:APPA), a specialty pharmaceutical company, today announced it has received the final milestone payment of $2.5 million from an affiliate of Paul Capital Healthcare.

Emergent BioSolutions Inc. (NYSE:EBS) announced today preliminary, unaudited financial results for 2009 and guidance for 2010.

EpiCept Corporation (NASDAQ: EPCT) Shares of Epicept Corp. soared over 30% today as the company announced an exclusive commercialization agreement for Ceplene with a leading international specialty pharmaceutical company Meda AB which is based in Stockholm. Celplene is EpiCepts novel therapy for the remission maintenance and prevention of relapse of patients with acute myeloid leukemia.

Generex Biotechnology Corporation (NASDAQ: GNBT) announced today that it has reached an agreement with a major Pharmacy chain to market the companies proprietary 7 Day Diet Aid Spray CRAVE-NX(TM) throughout the chains 7,000 stores. The product will arrive on the shelves beginning in January 2010.

Human Genome Sciences, Inc. (Nasdaq: HGSI) today will announce its priority goals for 2010 and report on the Company’s increasing momentum toward commercialization of late-stage products for systemic lupus and chronic hepatitis C in a presentation by H. Thomas Watkins, President and Chief Executive Officer, to financial analysts and investors at the 28th Annual JPMorgan Healthcare Conference in San Francisco.

Illumina, Inc. (NASDAQ:ILMN) today announced the HumanOmniExpress BeadChip (OmniExpress), the newest addition to the Omni family of microarrays for genome-wide association studies (GWAS).

Imaging3(TM) Inc., (OTC BB:IMGG.OB) will host a conference call on Tuesday January 12th at 1PM PST to update investors with regards to the companies 510k FDA submission. The FDA is currently seeking additional information and IMGG CEO Mr. Dean Janes will discuss the companies plans to address these questions with shareholders.

MAP Pharma (NASDAQ:MAPP) said to today that a second efficacy trial will not be required by the FDA for Levadex, the companies experimental ,orally inhaled migraine drug. MAP announced that the phase III trial sufficiently met all four primary endpoints. Shares rose nearly 33% in Monday trading.

NanoViricides, Inc. (OTC BB: NNVC.OB) (the "Company"), reports that the Company has been invited to present on January 12th at the Biotech Showcase™, a conference designed to showcase promising companies and technologies for partnering and investment purposes.

PhotoMedex (Nasdaq: PHMD) and Galderma Laboratories, L.P. have entered into a co-promotion agreement for Galderma’s photodynamic therapy application for the treatment of actinic keratoses (“AK”).

Quidel Corporation (NASDAQ:QDEL), a leading provider of rapid point-of-care diagnostic tests, announced today the signing of a definitive agreement to acquire privately held Diagnostic Hybrids, Inc. for approximately $130 million in cash.

QuantRx® Biomedical Corporation (OTCBB: QTXB), a broad-based diagnostic company focused on the development and commercialization of innovative diagnostic products, announced today that Walter Witoshkin, Chairman and Chief Executive Officer, will present at the OneMedForum 2010 Emerging Company Finance Conference in San Francisco, CA, on Wednesday, January 13, 2010.

Teleflex Incorporated (NYSE:TFX) has announced the appointment of Richard (Randy) Meier as executive vice president and chief financial officer, effective the close of business today.

Trimeris, Inc. (NASDAQ: TRMS) (“Trimeris” or the “Company”), a biopharmaceutical company engaged in the commercialization of therapeutic agents for the treatment of HIV, today announced that it has received a NASDAQ Staff determination letter dated January 5, 2010, notifying the Company that its common stock is subject to delisting due to the Company’s failure to hold its required annual meeting for fiscal year 2009.

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) today provided an update on key 2010 business priorities in conjunction with the 28th Annual J.P. Morgan Health Care Conference in San Francisco.

Targacept, Inc. (Nasdaq: TRGT), a clinical-stage biopharmaceutical company developing a new class of drugs known as NNR Therapeutics™, today announced that its collaboration and license agreement with AstraZeneca for the global development and commercialization of TC-5214 for major depressive disorder (MDD) has become effective as a result of early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act.

VIVUS,Inc (NASDAQ:VVUS) shares headed north on Monday following news that its Phase III erectile-dysfunction drug candidate avanafil was effective within use of 15 minutes for the majority of the patients in the study.

Walgreens (NYSE, NASDAQ: WAG), which is offering H1N1 vaccinations at all of its pharmacies and Take Care Clinics nationwide, has administered more than one million H1N1 vaccinations to date this season – as widespread vaccine availability and greater access enable more people to get vaccinated.

ZymoGenetics, Inc. (Nasdaq:ZGEN) today announced that its underwriters fully exercised their overallotment option to purchase an additional 2,100,000 shares of its common stock in connection with its previously announced public offering that priced on January 7, 2010.

"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus